Published in

American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 9(62), 2018

DOI: 10.1128/aac.00344-18

Links

Tools

Export citation

Search in Google Scholar

Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis

Journal article published in 2018 by Paola M. V. Rancoita, Timothy M. Walker, A. Sarah Walker, Daniel Wilson, Guy Thwaites, Thuong Nguyen Thuy Thuong, Baoli Zhu, Yanlin Zhou, Pang Yu, Federica Cugnata, Ana Luíza Gibertoni Cruz, Emanuele Borroni ORCID, Sarah J. Hoosdally, Clara Grazian, Timothy J. Davies and other authors.
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Orange circle
Published version: archiving restricted
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The UKMYC5 plate is a 96-well microtiter plate designed by the CRyPTIC Consortium (Comprehensive Resistance Prediction for Tuberculosis: an International Consortium) to enable the measurement of MICs of 14 different antituberculosis (anti-TB) compounds for >30,000 clinical Mycobacterium tuberculosis isolates. Unlike the MYCOTB plate, on which the UKMYC5 plate is based, the UKMYC5 plate includes two new (bedaquiline and delamanid) and two repurposed (clofazimine and linezolid) compounds.